Showing results (1-10 of 38) with videos related to
Sort By:
Pageof 4
Diabetes Technology & Therapeutics|February 17, 2009
Detection of hypoglycemia with continuous interstitial and traditional blood glucose monitoring using the FreeStyle Navigator Continuous Glucose Monitoring SystemGeoffrey McGarraugh, Richard BergenstalCurrent Medical Research and Opinion|February 13, 2009
Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylureaRichard Bergenstal, Andrew Lewin, Timothy Bailey, et al.Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|May 21, 2009
Diurnal glucose patterns of exenatide once weekly: a 1-year study using continuous glucose monitoring with ambulatory glucose profile analysisRoger Mazze, Ellie Strock, Blaine Morgan, et al.Diabetes/Metabolism Research and Reviews|June 2, 2026
Predicting the Complex, Multilevel Ecology of US County-Level Diabetes Prevalence: A Cross-Sectional, Artificial Intelligence AnalysisNicolaas P Pronk, Shuaijie Wang, Richard Bergenstal, et al.Journal of Diabetes Science and Technology|November 25, 2017
Time Savings Using a Standardized Glucose Reporting System and Ambulatory Glucose ProfileDeborah M Mullen, Richard Bergenstal, Amy Criego, et al.Blood Pressure|March 18, 2005
Undetected, uncontrolled blood pressure in type 2 diabetes: self-monitored blood pressure profilesRoger S Mazze, Rachel Robinson, Gregg Simonson, et al.Diabetes Technology & Therapeutics|May 14, 2008
Characterizing glucose exposure for individuals with normal glucose tolerance using continuous glucose monitoring and ambulatory glucose profile analysisRoger S Mazze, Ellie Strock, David Wesley, et al.Diabetes Technology & Therapeutics|July 16, 2021
Ultrarapid Lispro Demonstrates Similar Time in Target Range to Lispro with a Hybrid Closed-Loop SystemBruce Bode, Anders Carlson, Rong Liu, et al.Diabetes Care|September 7, 2014
New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2)Hannele Yki-Järvinen, Richard Bergenstal, Monika Ziemen, et al.Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|February 27, 2020
InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring-Study DesignTadej Battelino, Zsolt Bosnyak, Thomas Danne, et al.Pageof 4